Candesartan cilexetil: Comparison of once-daily versus twice-daily administration for systemic hypertension

Clinical Therapeutics

Volumn 21, Issue 3, 1999, Pages 464-474

  Zuschke, Christen A ^a   Keys, Iris ^b   Munger, Mark A ^c   Carr, Albert A ^d   Marinides, George N ^e   Flanagan, Terry L ^f   Cushing, Daniel J ^f   Hayes, Jodi L ^f   Michelson, Eric L ^a,f  

^a SE Emergency Physicians ^*  (United States)

^b Clinical Research Unit   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d Circulatory Disease Center   (United States)

^e Nephrology Associates   (United States)

^f Astra Pharmaceuticals   (United States)

Author keywords

Angiotensin II receptor blocker; Candesartan cilexetil; Systemic hypertension

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; UPPER RESPIRATORY TRACT INFECTION; VERTIGO;

EID: 0032894426     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)88302-2     Document Type: Article

References (20)

1. 1. Goodfriend TL, Elliott ME, Catt K.J. Angiotensin receptors and their antagonists. NEJM. 1996:334:1649-1654.
2. 2. Liao Y, Husain A. The chymase-angiotensin system in humans: Biochemistry, molecular biology and potential role in cardiovascular diseases. Can J Cardiol. 1995; 11 (Suppl F):13F-19F.
3. 3. Gavras I, Gavras H. Angiotensin II-possible adverse effects on arteries, heart, brain, and kidney: Experimental, clinical, and epidemiological evidence. In: Robertson JTS, Nicholls MG, eds. The Renin-Angiotensin System, London: Gower Medical Publishing; 1993:40.1-40.11.
4. 4. Gifford RW. Antihypertensive therapy. Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, and calcium antagonists. Essential Hypertens. 1997;81:1319-1333.
5. 5. Messerli FH, Weber MA, Brunner HR. Angiotensin II receptor inhibition. A new therapeutic principle. Arch Intern Med. 1996; 156:1957-1965.
6. 6. Shibouta Y, Inada Y, Ojima M, et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[ [2′-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (±)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[ [2′-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116). J Pharmacot Exp Ther. 1993;265:114-120.
7. 7. Kenakin T, ed. Competitive antagonism. In: Pharmacologie Analysis of Drug-Receptor Interaction. 3rd ed. Philadelphia: Lippincott-Raven Publishers; 1997:331-373.
8. 8. Belz GG, Fuchs B, Malerezyk C, et al. Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers. J Hum Hypertens. 1997;1 2(Suppl 2):S45-S47.
9. 9. Malerczyk C, Fuchs B, Belz GG, et al. Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man. Br J Clin Pharmacol. 1998;45:567-573.
10. 10. Nishikawa K, Naka T, Chatani F, et al. Candesartan cilexetil: A review of its pre-clinical pharmacology. J Hum Hypertens, 1997;11(Suppl 2):S9-S17.
11. 14C-candesartan cilexetil in healthy volunteers. J Hum Hypertens. 1997;11(Suppl 2):S27-S28.
12. 12. Elmfeldt D, George M, Hübner R, et al. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens, 1997;11(Suppl 2):S49-S53.
13. 13. Heuer HJ, Schöndorfer G, Högemann AM. Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens. 1997;11(Suppl 2):S55-S56.
14. 14. Reif M, White WB, Fagan TC, et al. Effects of candesartan cilexetil in patients with systemic hypertension. Am J Cardiol. 1998;82:961-965.
15. 15. Bell TP, DeQuattrao V, Lasseter KC, et al. Effective dose range of candesartan cilexetil for systemic hypertension. Am J Cardiol. 1999:83:272-275.
16. 16. Cozaar [package insert]. Westpoint, Pa: Merck & Co., Inc.; 1997.
17. 17. Vasotec [package insert]. Westpoint, Pa: Merck & Co., Inc.; 1997.
18. 18. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997; 157;2413-2446.
19. 19. Lipicky RJ. Trough:peak ratio: The rationale behind the United States Food and Drug Administration recommendations. J Hypertens. 1994;12(Suppl 8):S17-S18.
20. 20. Belcher G, Hübner R, George M, et al. Candesartan cilexetil: Safety and tolerability in healthy volunteers and patients with hypertension. J Hum Hypertens. 1997;11(Suppl 2):S85-S89.